H.C. Wainwright Reiterates Their Buy Rating on Aptose Biosciences

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO) today and set a price target of $6. The company’s shares opened today at $4.12, close to its 52-week high of $4.39.

Pantginis noted:

“We review the data below, but a quite a large amount of effort went into procuring the broad set of patient samples including: (1) maintaining integrity of the fresh sample (need to be tested immediately); (2) high expense for procurement and experiments; and (3) obtaining patient permission to use samples. and investigators presented strong potency of the drug against a broad set of primary AML and CLL patient samples (188 AML and 95 CLL samples) compared to other leading drugs. CG-806 exhibited greater potency against a broad set of AML samples compared to other FLT3 inhibitors (midostaurin, gilteritinib, quizartinib, sorafenib, crenolanib, and dovitinib). Further, CG-806 exhibited greater potency and ranges of activity than ibrutinib on patient-derived CLL samples. Al of this primary tumor sample work was completed under the Beat AML initiative.”

According to, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.4% and a 37.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Checkpoint Therapeutics Inc.

Currently, the analyst consensus on Aptose Biosciences is Strong Buy and the average price target is $6.33, representing a 53.6% upside.

In a report issued on June 5, Roth Capital also reiterated a Buy rating on the stock with a $6 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.39 and a one-year low of $1.07. Currently, Aptose Biosciences has an average volume of 359.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806 a non-covalent small molecule therapeutic agent.

From Our Partners